Argus upgraded Pfizer (PFE) to Buy from Hold with a $35 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Apellis appoints Mikael Dolsten to board of directors
- Pfizer Ramps Up Obesity, mRNA Flu and Skin-Drug Bets
- Pfizer Quietly Advances New Obesity Shot With Fresh Phase 1 Study Update
- Pfizer Advances mRNA Flu Vaccine Pipeline With New Phase 2 Trial
- Pfizer’s Tranquillo Vitiligo Trial Nears Key Data Phase, Setting Up a New Dermatology Catalyst for PFE